• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, August 25, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Systemic treatment for brain metastasis in HER2-positive advanced breast cancer

Bioengineer by Bioengineer
September 13, 2023
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

“With these new drugs now available in clinical practice, we expect HER2+/HER2-low BC patients with BMs to live longer and to live better.” 

Oncotarget

Credit: 2023 Batista et al.

“With these new drugs now available in clinical practice, we expect HER2+/HER2-low BC patients with BMs to live longer and to live better.” 

BUFFALO, NY- September 13, 2023 – A new editorial paper was published in Oncotarget’s Volume 14 on July 7, 2023, entitled, “Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?”

In their new editorial, researchers Marta Vaz Batista, José Perez-Gracia, Inês Eiriz, Maria Gion, Antonio Llombart, Sofia Braga, and Javier Cortés from Medica Scientia Innovation Research (MEDSIR) and Hospital Professor Doutor Fernando Fonseca discuss new drugs available for breast cancer (BC) patients with brain metastasis (BM). The better survival of Human Epidermal growth factor receptor-type 2 positive (HER2+) BC patients unmasked the biological predilection of this BC subtype for development of BM. 

Indeed, central nervous system (CNS) is a frequent metastatic site for HER2+ advanced BC patients. Over the last years, new therapeutic strategies targeting the HER2 protein have been introduced for systemic treatment of HER2+ BC – either tyrosine kinase inhibitors, monoclonal antibodies, or antibody-drug conjugates. Patients with BMs have a poorer outcome, compared with patients without BMs, but their prognosis is also improving with the introduction of new anti HER2+ – targeted therapies. 

“Our group has been working in the DEBBRAH trial, using trastuzumab deruxtecan for different settings of CNS involvement: stable or progressing BM and/or leptomeningeal carcinomatosis.”

The team included patients with HER2+ and HER2-low BC. Activity of trastuzumab-deruxtecan in patients with HER2+ BC and untreated or progressing after local therapy BMs also has been shown in another phase II trial.

“The final results are yet to be reported, but so far, we observed intracranial responses in HER2+ BC patients [7].”
 

Read the full editorial: DOI: https://doi.org/10.18632/oncotarget.28435 

Correspondence to: Marta Vaz Batista

Email: [email protected] 

Keywords: brain metastasis, HER2+ breast cancer
 

About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:

  • Twitter 
  • Facebook 
  • YouTube 
  • Instagram 
  • LinkedIn 
  • Pinterest 
  • LabTube
  • Soundcloud

 

Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28435 

Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact: [email protected].

 

Oncotarget Journal Office

6666 East Quaker Str., Suite 1A

Orchard Park, NY 14127

Phone: 1-800-922-0957 (option 2)

###



Journal

Oncotarget

DOI

10.18632/oncotarget.28435

Method of Research

Commentary/editorial

Subject of Research

People

Article Title

Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?

Article Publication Date

7-Jul-2023

Share12Tweet8Share2ShareShareShare2

Related Posts

Mediterranean Diet Plus Calorie Restriction and Exercise Cuts Type 2 Diabetes Risk by Nearly One-Third

August 25, 2025

Mediterranean Diet Combined with Exercise Reduces Diabetes Risk by 31% Through Calorie Control

August 25, 2025

High THC Concentrations Linked to Schizophrenia, Psychosis, and Adverse Mental Health Effects

August 25, 2025

Introducing a Breakthrough Tool to Monitor Infant Development Beginning at Just 16 Days Old

August 25, 2025

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    145 shares
    Share 58 Tweet 36
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Mediterranean Diet Plus Calorie Restriction and Exercise Cuts Type 2 Diabetes Risk by Nearly One-Third

Mediterranean Diet Combined with Exercise Reduces Diabetes Risk by 31% Through Calorie Control

High THC Concentrations Linked to Schizophrenia, Psychosis, and Adverse Mental Health Effects

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.